30037-41-3

Upstream product

• 875325-99-8 2-(Benzoylamino)-3-(4-hydroxy-3-methoxyphenyl)acrylsaeure 
• 18692-68-7 m-methoxy-p-acetoxy-α-benzoylaminocinnamic acid azlactone 
• 7440-02-0 nickel 
• 70723-31-8 (Z)-α-(benzamido)-β-(4-hydroxy-3-methoxyphenyl)acrylic acid 

Downstream Products

• 70723-31-8 (Z)-α-(benzamido)-β-(4-hydroxy-3-methoxyphenyl)acrylic acid 
• 300-48-1 3-O-methyldopa 

Relevant academic research and scientific papers

Asymmetric Catalyses. V. Enantioselective Amino Acid Synthesis by Hydrogenation of Prochiral Olefins with Rh-Complexes of the New Optically Active Chelating Phosphane Norphos

Racemic bicyclohept-5-ene-2,3-diylbis(diphenylphosphane oxide), NorphosO, can be resolved with (-)-di-O-benzoyltartaric acid, (-)-DBW.The X-ray structure analysis of the diastereomer (-)-NorphosO/(-)-DBW, which is less soluble in ethanol, exhibits strong hydrogen bonds between the carboxylic groups of DBW and the PO groups.The bonding of the DBW-carboxylic groups to different NorphosO units leads to the formation of infinite close-packed chains.From the internal comparison with (-)-DBW the absolute configuration follows as (2R,3R) for (-)-Norphos.The chelating phosphanes (+)- and (-)-Norphos, obtained by SiHCl3-reduction of (+)- and (-)-NorphosO, respectively, afford neutral and cationic Rh-complexes which, with H2 at room temperature and atmospheric pressure within a few hours, give quantitative hydrogenation of α-(acetylamino)cinnamic acid, α-(acetylamino)acrylic acid and Dopa precursors.The optical yields vary between 79 and 97percent.

A New Chiral Rhodium(I) Complex of (2R,3R)-2,3-Bis(diphenylphosphino)butane for Asymmetric Hydrogenations

Rhodium(I) complexes of the new chiral ligand (2R,3R)-2,3-bis(diphenylphosphino)butane (4) - which is easily prepared from natural tartaric acid - hydrogenate α-(acylamino)acrylic acids to natural (S)-acylamino acids in high chemical (95-100percent) and optical (80-100percent) yields.

Process for the preparation of l-dopa

The present invention is directed to preparing L-Dopa, an agent effective in the treatment of Parkinson's Disease, from a D,L-N-benzoyl-3-(4-hydroxy-3-methoxyphenyl) alanine utilizing dehydroabietylamine as a resolving agent and intermediates in this proc